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Dopaminetive animal model of Parkinson disease (PD) remains a critical unmet need.
Although toxin-induced PD models have served many useful purposes, they have generally failed to
recapitulate accurately the progressive process as well as the nature and distribution of the human
pathology. During the last decade or so, the identiﬁcation of several genes whose mutations are causative of
rare familial forms of PD has heralded in a new dawn for PD modelling. Numerous mammalian as well as non
mammalian models of genetically-linked PD have since been created. However, despite initial optimism,
none of these models turned out to be a perfect replica of PD. Meanwhile, genetic and toxin-induced models
alike continue to evolve towards mimicking the disease more faithfully. Notwithstanding this, current genetic
models have collectively illuminated several important pathways relevant to PD pathogenesis. Here, we have
attempted to provide a comprehensive discussion on existing genetic models of PD.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionParkinson disease (PD) is a prevalent neurodegenerative disorder
affecting millions of elderly individuals worldwide. Clinically, patients
with PD exhibit a characteristic motor phenotype commonly referred
to as “parkinsonism” that includes bradykinesia, postural instability,
rigidity and tremor [1]. Although PD is the major cause of parkinson-
ism, it is important to note that the disease is clinically and
pathologically distinguishable from other forms of parkinsonism.
The principal neuropathology that gives rise to the constellation of
primary motoric deﬁcits seen in PD patients is the loss of
dopaminergic neurons in the substantia nigra pars compacta (SNpc)
of the midbrain. This lesion results in a severe depletion of striatal
dopamine (DA) and thereby an impaired nigro-striatal system that
otherwise allows an individual to execute properly co-ordinated
movements. Accordingly, pharmacological replacement of brain DA
represents an effective symptomatic recourse for the PD patient, at
least during the initial stages of the disease. Thus, on a practical note,
one might regard the SN pathology as the most important hallmark of
PD. However, it is imperative for us to recognize that neurodegenera-
tion in PD frequently involves other areas of the brain such as the
dorsal motor nucleus of the vagus, locus ceruleus (LC) and olfactory
nuclei [2,3], and that non-motor features arising from these extra-h Laboratory, National Neuro-
ore. Tel.: +65 6357 7520; fax:
im).
ll rights reserved.nigral neuronal losses can be additional sources of considerable
consternation and disability for affected individuals [1]. Given this,
one should perhaps consider PD as a multi-system disorder. Another
key histological feature of PD is the presence of Lewy bodies (LBs) in
surviving neurons [4]. Despite decades of research, little is known to
date about how LBs are formed or whether these inclusion bodies
represent a cause, consequence or an epiphenomenon of the disease.
Notwithstanding this, Braak et al. have recently used LB as a marker
for PD pathogenesis and enumerated six neuropathological stages of
the disease which in essence, supports the notion that PD is a multi-
system disorder [2]. However, it should be noted that a correlation
between neuronal loss and LB burden is not taken into account in the
paper of Braak et al., and that emerging evidence suggests that LB
biogenesis may be a neuroprotective response [5,6].
Given its highly complex nature, it is apparently a tremendous
challenge to model PD accurately in experimental animals. Further-
more, the etiology of sporadic PD is less than straightforward,
potentially involving combinations of the aging process, genetic
propensity and environmental exposures [7–10]. Notably, before the
advent of genetic PD models, the majority of studies have relied on
neurotoxin intoxication to model PD-associated neuronal loss in
animals. These neurotoxin-based models have generally failed to
recapitulate accurately the progressive process that involves multiple
areas of the central nervous system dominated by the hallmark
aggregation of proteins into LBs in remaining neurons [11]. Another
common critique of thesemodels is the acute nature of the neurotoxin
treatment paradigm, which often “hurry” the degenerative process
that normally requires decades to surface in humans to mere days or
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pragmatic reasons, the caveat is that the mechanism underlying acute
neurotoxicity may not be reﬂective of that occurring in PD, where a
slower pace of neuronal death is seen. Clearly, a chronic disease model
would be more desirable. Indeed, toxin-inducedmodels of PD seem to
be evolving towards this direction. Notably, a recent study by Fornai et
al. demonstrated that continuous low-level exposure of mice to the
parkinsonian neurotoxin, MPTP, mimics many features of the disease
including progressive behavioural changes and formation of nigral
inclusion [12].
During the last decade or so, the identiﬁcation of several genes
whose mutations are causative of rare familial forms of PD has
heralded in a new dawn for PD modelling. Genetic models, unlike
their toxin-based counterparts, hold promise of reproducing the
chronic nature of the degenerative process as well as the nature and
distribution of the human pathology. However, despite initial
optimism, the endeavour insofar to generate a representative model
of PD based on the manipulation of PD-linked genes in experimental
animals has proven to be challenging. Nonetheless, a wealth of useful
information regarding the molecular events that surround PD
pathogenesis is created along with every new PD-linked gene being
modelled. Here, we have attempted to provide a comprehensive
review on existing genetic models of PD and discuss the valuable
insights obtained from these models.
2. Genetic models of PD
The ﬁrst gene to be unequivocally linked to familial PD is α-
synuclein [13]. Following this discovery in 1997, several other familial
PD-linked genes associated with autosomal dominant or recessive
forms of PD were subsequently identiﬁed. These include parkin [14],
DJ-1 [15], PINK1 [16], and LRRK2 [17,18]. It is noteworthy to mention
here that although mutations in UCHL1 [19] and Omi/HtrA2 [20] have
also been suggested to cause parkinsonism, their relevance to PD is
currently contentious because the purported disease-causing muta-
tion is either extremely rare in occurrence (e.g. UCHL1 I93M) or
present in control population at similar frequencies (e.g. Omi/HtrA2
G399S) [21]. As for the recently-described ATP13A2-linked parkinson-
ism [22], the associated clinical phenotype (characterized by mild
parkinsonism and prominent cognitive defects) is rather divergent
from classical PD and its relevance to PD is similarly debatable. In
general, PD-linked genes are expressed as transgenes in heterologous
organisms if their inheritance pattern in humans suggests a dominant
transmission. Otherwise, orthologous copies of the human gene are
ablated in animals to mimic recessive loss of gene function. To date,
several mouse models of familial parkinsonism, as well as ﬂy and
worm models, have been generated. Although the non-mammalian
PD models cannot recapitulate fully the phenotypic and pathologic
features of the human condition, they are nonetheless able to
reproduce certain salient hallmarks of PD such as LB-like inclusions
and DA neurodegeneration [23,24], and are therefore useful models to
study the relationship between PD-linked genes and DA neuronal
function. Notably, six DA neuronal clusters are recognizable in each of
the adult ﬂy brain hemispheres (Fig. 1A), while a total of eight
DA neurons organized into three subsets are found in the C. elegans
(Fig. 1B). Importantly, the well-characterized genetics of these non-
mammalian PD models offer a unique advantage over the mouse
model for the rapid identiﬁcation of modiﬁers that could illuminate
important pathways involved in disease pathogenesis, insights of
which could facilitate the subsequent development of novel
therapeutics.
2.1. Alpha-synuclein
α-Synuclein is a small (140 amino acids) but abundant neuronal
protein that is particularly enriched in pre-synaptic terminals.Although the precise physiological function of α-synuclein remains
to be elucidated, several studies have suggested a regulatory role for
the protein in membrane and vesicular dynamics [25,26]. It is
currently well established that mutations in the α-synuclein gene,
occurring as substitutions (A53T, A30P and E46K), duplication or
triplication, are causative of dominantly inherited forms of PD [13,27–
29]. Importantly, α-synuclein has been identiﬁed to be a major
structural component of LBs [30]. Collectively, these ﬁndings provide a
compelling case for modelling PD via the over expression of wild type
or mutant forms of α-synuclein in animals.
Masliah et al. developed the ﬁrst transgenic mousemodel that over
expresses wild type human α-synuclein [31]. They observed in these
mice a progressive accumulation of neuronal inclusions in the
neocortex, hippocampus and SN that stained positively with anti-
bodies toα-synuclein and ubiquitin. However, these inclusions are not
of a ﬁbrillar composition that otherwise characterizes LBs. Further,
there is no apparent loss of DA neurons in these mice. Although the
highest-expressing line exhibits signiﬁcant degeneration of TH-
positive nerve terminals within the striatum that is accompanied by
motor impairment on a rotarod, the degeneration pattern is distinct
from the profound DA cell loss seen in PD. Moreover, the observed
phenomenon is dissociated from inclusions formation, as other
neuronal subtypes in same line and also the same subset of neurons
in other lines that are all burdened by inclusions are spared from
degeneration. However, as mentioned earlier, it is currently unclear
whether neuronal loss and inclusions load are linked in a causative
manner. Notwithstanding this, the α-synuclein mouse model of PD
generated by Masliah et al., although insightful, does not appear to
recapitulate faithfully the human pathology. This less than robust PD
phenotype exhibited by Masliah's mice is essentially a recurring
theme of many more α-synuclein mouse models that followed, which
differ principally from each other in the promoter used and whether
the human α-synuclein transgene is a wild type or mutated copy
(Table 1). It is noteworthy that several of these models that relied on
the prion or Thy-1 promoter to drive high levels of wild type or
mutant α-synuclein expression produce widespread extra-nigral
pathology, including motor neuron degeneration and glial pathology
in some, which on the whole is less reﬂective of PD than of
synucleinopathies [32–35]. To achieve a more localized effect of α-
synuclein over expression, a number of groups have generated α-
synuclein lines using the TH promoter, which directs expression
speciﬁcally in catecholaminergic neurons. Notwithstanding the
obvious limitation of this approach in modelling the broad α-
synuclein pathology that characterizes the human disease, TH-driven
wild type, A53T or A30P α-synuclein mice similarly fail to enhance DA
cell loss [36,37]. Further, these mice also tend to lack α-synuclein-
positive inclusions [36,37]. A notable exception is a TH-synuclein line
that expresses a doubly mutated (A30P/A53T) form of human α-
synuclein, which represents one the few genetic models to date to
show an apparent, age-dependent, loss of TH-positive neurons in the
SNpc that is accompanied by a decline in motor activity, albeit in the
absence of detectable neuronal aggregates [38]. However, it is
currently unclear whether the observed phenomenon could have
arisen from a regulatory effect of the α-synuclein double mutant on
TH expression. Further, the patho-physiological relevance of doubly
mutated α-synuclein is questionable, as none has reported its
occurrence in familial PD cases thus far. Nonetheless, these mice are
potentially useful for understanding how aberrant forms of α-
synuclein could trigger DA neurotoxicity. More recently, two groups
have independently generated transgenic mice over expressing
truncated forms of α-synuclein under the direction of the TH
promoter [39,40]. The motivation for this came from several previous
in vitro studies suggesting that C-terminally truncated α-synuclein
(α-SynΔC)may be pathologically relevant [41–44], as well as from the
observation by Lee et al. that these proteolytically-processed forms of
α-synuclein accumulate in A53T-synuclein-expressing mice
Fig. 1. DA system in Drosophila and C. elegans. (A) Schematic ﬁgure (top panels) and anti-TH-immunostained images (bottom panels) showing the distribution of various DA
neuronal clusters in the ﬂy brain. PAL, protocerebral anterior lateral; PAM, paired anterolateral medial; PPM, protocerebral posterior medial; PPL, protocerebral posterior lateral. (B)
Schematic depiction of DA neuronal subsets in the worm. CEP, cephalic cells (2 dorsal and 2 ventral); ADE, anterior deirids (2 bilateral); PDE, posterior dierids (2 bilateral).
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[33]. Moreover, in a follow-up study, the group led by Lee demon-
strated that α-SynΔC species are enriched in α-synuclein-positive
aggregates and that disease-associated mutations promote their
accumulation [45]. Further,α-SynΔC enhances the in vitro aggregation
of the full-length protein, thereby promoting its dysfunction. Inter-Table 1
α-Synuclein mouse models
Transgene Promoter Nigral
cell loss
Protein
inclusions
Motor
impairment
Additional features
WT PDGF-β − + + Inclusions are non-ﬁbrilla
WT Thy-1 − + + Also noted motor neuron
A53T − + +
WT Prp − − − No obvious neurological d
A30P − − −
A53T Prp − + + Pathology abundant in bra
A30P Prp − − + Widespread CNS gliosis. T
WT TH − − n.d. Levels of striatal DA uncha
A53T or A30P − − n.d.
WT TH − − − Signiﬁcant reduction in lo
A53T/A30P TH + − + Also exhibit age-related re
WT (1–120) TH − + + Inclusions in SN and olfac
A53T (1–130) TH + − + Selective but non-progres
WT CaMKIIα +/− − + Conditional model. Mice e
n.d. not described.estingly, one of the truncated α-synuclein models generated that
expresses a 130 amino acid-containing version of the protein exhibit a
remarkable and selective degeneration of nigral DA neurons that is
associated with impaired locomotory function [40]. Importantly, the
motoric abnormality could be reversed by L-DOPA treatment, a
phenomenon that recapitulates the human condition. Unfortunately,Ref.
r. [31]
and brain stem pathology in these mice. [34]
ysfunction despite high levels of transgene expression [32,33]
in stem and other brain areas. Truncated α-synuclein species observed. [32,33]
runcated α-synuclein species observed. [35]
nged in transgenic animals compared to control littermates. [36]
comotor activity compared to control mice following MPTP treatment. [37]
duction in DA level. [37,38]
tory bulb. Transgenic mice lack endogenous a-synuclein. Reduced striatal DA. [39]
sive loss of A9 (but not A10) DA cells. Occurs during embryogenesis. [40]
xhibit modest SNr degeneration and cognitive impairments. [46]
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embryogenesis [40]. Moreover, α-synuclein-positive inclusions are
absent in these mice. Although ﬁbrillar α-synuclein inclusions are
detected in the other truncated α-synuclein model that expresses a 120
amino acid-containing protein, their presence is not accompanied by
the loss of nigral DA neurons [39]. Meanwhile, the α-synuclein mouse
model continues to evolve. Earlier this year, Nuber et al. described a
novel transgenicα-synucleinmousemodel that expresses thewild type
protein under a tetracycline (tet)-regulatable system [46]. The
Germany-based investigators demonstrated in these mice a modest
loss of neurons principally in the reticulata zone of the SN that is
nonetheless accompanied by progressive motor decline. Further, they
also observed hippocampal pathology, associated cognitive impairment,
and interestingly, reduced neurogenesis in these mice upon turning on
the transgene expression for a period of time. All these phenotypic
alterations however occur in the absence of ﬁbrillary inclusions.
Importantly, the cessation of transgene expression mitigates progres-
sion of the phenotype but did not reverse the symptoms, suggesting
that the continual expression of α-synuclein is required for disease
progression. It is noteworthy to mention that prior to this demonstra-
tion by Nuber et al., the question on whether disease progression
mediated by the expressed transgene could be halted or reversed after
its onset by turning off the transgene expression could not be explored.
The conditional model that Nuber et al. have generated thus represents
an important advance in α-synuclein modelling.
In summary, despite the initial excitement, none of the α-
synuclein mouse models generated thus far replicates the human
disease faithfully. Indeed, ﬁbrillary inclusions are found lacking in the
majority of these models, and SNpc cell loss is, more often than not,
non-existent in α-synuclein-expressing mice. Some investigators
have suggested that the absence of frank nigral pathology in the
variousα-synuclein mousemodels is due to the inherent resistance of
rodent's nigral neurons to degeneration [33]. This is debatable, as the
expression of both the truncated and doubly-mutated forms of α-
synuclein could promote the loss of TH-positive neurons in the SNpc
[38,40]. Moreover, direct delivery of α-synuclein-containing viral
vectors into the SN of rats and mice alike via stereotactic injections
result in DA neurodegeneration [47–49]. Indeed, the use of viral
vectors to over-express PD-linked genes represents an alternative and
important way tomodel PD in rodents (Excellent reviews on this topic
have been written elsewhere, for example see [50]). At least in
rodents, it thus appears that a threshold expression level (achieved by
viral delivery) or some modiﬁcations (achieved by truncation or
double mutation) is needed for α-synuclein to manifest its toxicity in
DA neurons.
In sharp contrast to the general lack of PD phenotype in α-
synuclein mouse models, transgenic ﬂies over expressing α-synuclein
surprisingly exhibit robust signs of parkinsonism. Concurrent to the
report of Masliah et al. of the ﬁrst α-synuclein-expressing mice, Feany
and Bender reported the ﬁrst Drosophila model of PD that was
generated via directed expression of wild type or mutant forms (A53T
and A30P) of humanα-synuclein in the nervous system of the ﬂy [51].
Remarkably, transgenic ﬂies over expressing wild type or mutant α-
synuclein exhibit an adult-onset, age-dependent loss of dorsomedial
clusters (DMCs) of DA neurons that is accompanied by a progressive
loss of climbing ability. Further, these ﬂies also developed intraneur-
onal α-synuclein-positive inclusions that resemble LBs. Importantly,
inclusions formation parallels α-synuclein-induced toxicity both
spatially and temporally. The ﬂy model developed by Feany and
Bender thus recapitulates the salient features of PD, including disease
onset at adulthood, progressive locomotion deﬁcit that is associated
with an age-dependent and selective loss of DA neurons, and
formation of ﬁbrillar α-synuclein inclusions. Given this, and its
amenability to genetic screen for modiﬁers, the α-synuclein ﬂy
model offers a valuable tool to elucidate suppressors of α-synuclein-
mediated toxicity. At the same time, the model also allows for thedirect assessment of candidate suppressor function in vivo, which is
less time consuming than unbiased genetic screens. Using the
candidate approach, Auluck et al. demonstrated that co-expression
of Hsp70 with α-synuclein reduces α-synuclein aggregation and
concomitantly attenuates α-synuclein-mediated DA neuronal death
in ﬂies, a ﬁnding corroborated later by others in mice [52,53].
Consistent with this, transgenic ﬂies fed with geldanamycin, an
enhancer of Hsp70 expression and a modulator of stress response,
similarly suppresses α-synuclein toxicity [54,55]. Together, these
studies suggest a neuroprotective role of Hsp70 against α-synuclein-
mediated toxicity, and provide a good illustration of the utility of the
Drosophila PD model in facilitating the discovery of compounds of
therapeutic potential. Interestingly, the neurprotective effect of
geldanamycin appears to be uncoupled from inclusion formation, i.e.
in the presence of geldanamycin, DA neurons are spared from
degeneration despite the continued presence of inclusion pathology
[55]. Consistent with this, Chen and Feany observed a reciprocal
relationship between aggregate formation and neurotoxicity in ﬂies
harbouring a missense mutation (S129A) on α-synuclein that renders
the expressed protein inert to phosphorylation at Ser129 [56], the
modiﬁcation of which has been associated with ﬁbril formation and
enhanced neurotoxicity [57]. Notably, the S129A mutation markedly
increases inclusion body formation and also abrogates α-synuclein
toxicity. Conversely, the alteration of Ser129 to the negatively charged
residue aspartate that mimics phosphorylation apparently favors the
maintenance of α-synuclein in a soluble, toxic form and signiﬁcantly
enhances α-synuclein-mediated toxicity in ﬂies. Thus, the phosphor-
ylation status of Ser129 appears crucial in mediating α-synuclein
neurotoxicity and inclusion formation. However, in mice expressing
full length α-synuclein, this residue appears to be constitutively
phosphorylated but the modiﬁcation alone is clearly insufﬁcient to
trigger neurodegeneration in these animals [58].
As with the mouse models, controversies also surround the Dro-
sophila α-synuclein model. Whereas Feany and Bender reported
complete (or near complete) loss of DA neurons in the DMCs in 30-
day-old transgenic ﬂies [51], Auluck et al. observed only a 50% loss in
the same subset of DA neurons [52], a ﬁnding later corroborated by
another group [59]. Notably, parafﬁn sections of ﬂy brains were
analyzed in these studies. A more recent study that assayed DA
neurons in α-synuclein-expressing ﬂies by means of whole-mount
immunohistochemistry coupled with confocal microscopy (which
allowed the simultaneous viewing of all DMC neurons in a single
preparation) failed to detect any signiﬁcant DA cell loss [60]. Given
these discrepancies, one needs to interpret the results obtained from
various Drosophila α-synuclein models with caution, particularly
when the choice of assay could potentially inﬂuence the observation
made. In an attempt to optimize the method for the histological
detection of DA neurons in ﬂies, Drobysheva et al. has very recently
demonstrated that discrepancies in DA neuronal staining could arise
from the ﬁxative used, method of ﬁxative delivery, sectioning
technique and choice of antibodies [61]. Notably, parafﬁn sections
were found to be inconsistent in preserving DA epitopes. In the same
report, the authors also suggested an optimized protocol for DA
neuronal staining in Drosophila that combines a weak ﬁxative with
cooled microwave inﬁltration, buffers that provide anti-oxidant
protection of DA epitopes and agarose embedding coupled with
thick sectioning on a vibratome. Whether the described method for
DA neurons detection in ﬂies is more sensitive than confocal
microscopy-aided whole mount analysis currently awaits evaluation
by other groups.
Along with ﬂy and mouse models, PD investigators have also
created C. elegans expressing α-synuclein. Lakso et al. reported a C.
elegans α-synuclein model that over expresses wild type or mutant
(A53T) forms of the protein [24]. They demonstrated in these
transgenic worms an accelerated loss of all three subsets of the
nematode's DA neurons following DA neuronal-speciﬁc expression of
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accompanied by inclusions formation normotoric deﬁcits. Notably, DA
neurons in C. elegans are thought to function as mechanosensors that
have the capacity to modulate but not control movements. Consistent
with this, pan-neuronal or motor neuronal-speciﬁc expression of α-
synuclein in C. elegans results in signiﬁcant motor neuron degenera-
tion and concomitantly compromised its motor ability [24]. A
subsequent model developed by Kuwahara et al. which over-
expresses mutant A53T or A30P human α-synuclein in a DA neuron-
speciﬁc manner exhibits abnormal food sensing behaviour linked to
DA neuronal dysfunction, albeit without overt cell loss [62]. This
behavioural abnormality was accompanied by a reduction in neuronal
DA content and was alleviated by the administration of exogenous DA.
Similar to Lakso's model, the investigators did not detect the presence
of LB-like inclusions in these worms. More recently, Ham et al.
described a C. elegans α-synuclein model that developed inclusions,
but in its body wall muscles because a muscle-speciﬁc promoter was
used to drive the transgene expression [63]. Importantly, a genome
wide RNAi screening performed revealed suppressor roles of several
age-related genes, including sir-2.1/SIRT1 and lagr-1/LASS2, in α-
synuclein-mediated inclusions formation, thereby suggesting a link
between cellular aging and inclusions biogenesis. In a separate RNAi
screen and as a follow-up study, Kuwahara et al. uncovered four genes
related to the endocytic pathways that cause severe growth/motor
abnormalities selectively in α-synuclein transgenic worms [64]. This
ﬁnding suggests a relationship between aberrant endocytosis and α-
synuclein-mediated neuronal dysfunction. Together, the worm and ﬂy
models of α-synuclein provide further support for a neurotoxic role of
α-synuclein accumulation, and importantly, helped to illuminate
potential pathways involved in α-synuclein-mediated pathology.
2.2. Parkin
Shortly after the discovery of α-synuclein as a familial PD-linked
gene, mutations in the parkin gene were reported to be causative of
autosomal recessive juvenile parkinsonism (ARJP) [14]. Following this
association, three independent groups demonstrated that parkin
functions as a ubiquitin ligase associated with proteasomal degrada-
tion and that disease-causing mutations of parkin compromise its
normal role as an E3 enzyme [65–67]. A logical working hypothesis
that ensued is that loss of parkin function leads to a neurotoxic
accumulation of one or several of its substrates. Indeed, numerous
reported substrates of parkin, including CDCrel1 [68], CDCrel2a [68],
Cyclin E [69], Pael-R [70], AIMP2/p38 [71,72] and FBP1 [73], were later
found to accumulate in the brains of PD patients carrying parkin
mutations. However, as none of the parkin substrates identiﬁed thus
far is exclusively expressed in DA neurons, it remains puzzling why DA
neurons in familial parkinsonism linked to parkin mutations areTable 2
Mouse models of autosomal recessive parkinsonism
Ablated gene Exon
deleted
Nigral
cell loss
Protein
inclusions
Motor
impairment
Additiona
Parkin 3 − − − Increased
Parkin 3 − − + Reduced
Parkin 2 − − − Normal n
Parkin 7 − − − Loss of LC
PINK1 4–7 − − − Reduced
DJ-1 2 − − + Increased
DJ-1 1–5 − − + Increased
DJ-1 2 − − + No differe
DJ-1 7⁎ − n.d. +/− Enhanced
DJ-1 2–3 − n.d. − Increased
DJ-1 3–5 − n.d. − Hypoloco
n.d. not described.
⁎ Translation blocked.selectively vulnerable to deﬁcient parkin function. Nonetheless,
because parkin mutations are classically transmitted in a recessive
manner, there wasmuch optimism amongst PD investigators to create
a representative model mimicking parkin-related parkinsonism
through the ablation of orthologous parkin gene in the animal.
Further, because parkin-related cases are usually devoid of classic LBs
[74–76], assessment of the anticipated pathology in parkin null mice
also appears more straightforward.
In 2003, Goldberg et al. and Itier et al. independently reported the
characterization of parkin null mice that were created via the deletion
of murine parkin exon 3 [77,78]. Soon after, two other groups
respectively generated exon 2- and exon-7-deleted parkin mice
[79,80]. Although all of them conﬁrmed the abolition of parkin
mRNA and protein expression in their respective models, none of
these parkin null models exhibit apparent signs of parkinsonism
(Table 2). Consistent with this, the neurological mouse mutant qua-
kingviable (qkv), which was recently identiﬁed to be parkin-deﬁcient
due to the spontaneous deletion of a genetic region that consisted of
the murine parkin gene, displays no loss of DA neurons [81,82].
Furthermore, despite the association of parkin function with protein
degradation, the majority of previously identiﬁed parkin substrates
(except AIMP2/p38 and FBP1) do not show any detectable accumula-
tion in these mice [72,73,77–80]. Although the levels of AIMP2/p38
and FBP1 are elevated in the brains of parkin null mice [72,73], this
phenomenon is currently conﬁned to the parkin exon 7-deleted line,
i.e. whether the same is observed in other parkin knockout lines
awaits conﬁrmation. Interestingly, the same line also exhibits nora-
drenergic dysfunction due to a signiﬁcant, albeit non-progressive, loss
of locus coeruleus (LC) neurons [80]. However, it is not entirely clear at
this moment why this deﬁcit is not seen in other lines. Moreover,
parkin-deﬁcient qkv mutant exhibit an opposite phenotype, i.e.
increase in LC neurons [83]. In the case of exon 3-deleted parkin
mice, biochemical and proteomic analyses of brain samples from these
mice revealed deﬁcits in dopamine handling, reduced mitochondrial
respiration and antioxidant capacity, as well as increased ROS-
mediated damage [77,78,84]. Further, primary midbrain neuronal
cultures prepared from one of these lines exhibit increased suscept-
ibility to neurotoxicity elicited by rotenone, a PD-linked mitochondrial
poison, compared to control cultures [85]. These features are consistent
with the implicated cellular roles of parkin in regulating mitochondrial
function and conferring protection against oxidative stress [86–89].
Further supporting this, virus-mediated delivery of parkin prevents
dopaminergic neurodegeneration in rats either overexpressing α-
synuclein [90,91] or treated with 6-OHDA [92], as well as in mice
treated with MPTP [93], although conﬂicting observations have also
been reported [94]. In the Drosophila system, we and others have
similarly observed an intimate functional relationship between parkin
and the mitochondria (discussed below). Indeed, mitochondriall features Ref.
extracellular DA level. [77]
DAT and VMAT levels. Cognitive deﬁcits. [78]
eurochemistry. No robust phenotype. [79]
neurons. Reduced acoustic startle. [80]
evoked DA release. Impaired mitochondrial respiration in striatum. [123,124]
DA reuptake. Reduced evoked DA release. [132,133]
DA reuptake. [134]
nce in evoked DA release compared to WT. [135]
DAT levels in presynaptic membranes [136]
mitochondrial H2O2 production [137]
motion observed only in response to amphetamine or MPTP challenge. [141]
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phila parkin mutants generated thus far.
The Drosophila parkin gene encodes a protein that bears a high
degree of sequence similarity to the human parkin protein [95,96].
Overall, the amino acid identity between ﬂy and human parkin is 46%,
but the sequence conservation between their respective catalytic
(RING-IBR-RING) region is even higher (56% amino acid identity),
suggesting an evolutionary conserved function. Using an established
P-element mutagenesis strategy, the group led by Leo Pallanck
originally developed ﬂies devoid of endogenous parkin gene [95].
These parkin null ﬂies are semi-viable and display reduced lifespan,
locomotor defects and male sterility. However, the initial assessment
of TH-positive neurons in parafﬁn-embedded head sections revealed
no obvious loss of DA neurons, although cells in the DMCs showed
shrinkage of the cell body and decreased TH-staining [97]. These
observations were subsequently corroborated by another group, who
further found that c-Jun terminal kinase (JNK) is activated in the
dorsomedial DA neurons of parkin null ﬂies, thereby suggesting a
negative role for parkin in JNK signalling pathway and at the same
time, a pathogenic mechanism involving JNK activiation in parkin-
related neurodegeneration [97]. The Pallanck's group later discovered
that a substantial variance in sample analysis might have obscured a
subtle loss of neurons in their parkin null ﬂy model. Following a re-
analysis by the same group using the more sensitive, confocal
microscopy-based quantiﬁcation method, the investigators demon-
strated in parkin null ﬂies a signiﬁcant and progressive degeneration
of a subset of DA neurons known as the protocerebral posterior lateral
(PPL1) cluster [98]. However, a question that remained was whether
the loss of select subsets of DA neurons is sufﬁcient to trigger
locomotion defects in the Drosophila, as parkin null ﬂies also exhibit
marked defects in their musculature, which is plagued by pronounced
mitochondrial pathology and muscle degeneration [95,96]. None-
theless, mitochondrial dysfunction is commonly associated with
sporadic PD pathogenesis and it is conceivable that the mechanism
underlying muscle degeneration in ﬂies may be relevant to DA
neurodegeneration. Moreover, as discussed above, aberrant mito-
chondrial function also appears to be a feature of parkin null mice.
Further, in a related study, the deletion of parkin exons 1–4 in C.
elegans produces a mutant that show selective vulnerability to
mitochondrial complex I inhibitors [99], again implicating a functional
relationship between parkin and the mitochondrion. Thus, the
disruption of mitochondrial function appears to be a common feature
of parkin null animals. To elucidate the mechanism responsible for the
muscle pathology in parkin null ﬂies, the Pallanck's group performed a
genetic screen for parkin modiﬁers and found that loss-of-function
mutations in oxidative stress response components enhance the
phenotype of parkin mutant ﬂies [100]. One of these components is
glutathione S-transferase S1 (GstS1), an important cellular defence
component against oxidative stress. In a separate study by the same
group, the investigators found that overexpression of GstS1 also
prevents DA neurodegeneration in parkinmutant ﬂies, suggesting that
the induction of GstS1 expression could be useful in the treatment of
parkin-related PD [98].
Although the ablation of orthologous parkin gene in animals is an
appropriate approach to model its apparent loss-of-function in
parkin-related PD, numerous reports suggest that single parkin
mutations alone may confer increased susceptibility to developing
the disease [101–104]. These include two case-control studies which
revealed the presence of several heterozygous parkin mutations that
are not found in control individuals [101,104]. However, the genetic
basis of this remains unclear, as most of the single parkinmutant allele
do not appear to transmit in an autosomal dominant fashion as might
be expected [105]. Two parkin mutations that frequently occur in
heterozygous state are R275W and G328E. To better understand the
effects of parkin mutations in vivo, we and others have recently
generated transgenic Drosophila expressing various parkin mutantsunder the control of a DA neuron-speciﬁc driver [106,107]. We
demonstrated in R275W, but not G328E, mutant parkin-expressing
ﬂies an age-dependent loss of DA neurons from the PPL1, and also
PAM, DA neuronal clusters. Importantly, by directing the expression of
the parkin mutant speciﬁcally in TH-positive neurons, we found that
DA neurodegeneration alone is sufﬁcient to trigger progressive
locomotion defects in these R275W parkin-expressing ﬂies [106].
Similar observations were made by Sang et al. with transgenic ﬂies
over expressing two other disease-associated parkin mutants [107].
Our results thus suggest a direct association between DA neurode-
generation and locomotor dysfunction in ﬂies, a phenomenon that is
seen in human PD patients. It is also noteworthy tomention that when
the R275W mutant is expressed speciﬁcally in the indirect ﬂight
muscles of ﬂies, it generated pleiomorphic mitochondrial abnormal-
ities [108]. Together, our results also suggest the interesting possibility
that certain parkin mutations may directly exert neurotoxicity in vivo.
Mechanistically, how select parkin mutants could mediate pathogenic
outcomes in the Drosophila remains to be elucidated. However, it is
tempting to propose that R275W parkin-mediated toxicity may be
related to the protein's propensity to aggregate, as we and others have
previously demonstrated in cultured cells [109–113]. Interestingly, C.
elegans carrying an in-frame deletion variant of pdr-1, a human
parkin ortholog, which exhibit altered solubility and intracellular
localization properties are hypersensitive to a variety of proteotoxic
conditions, including ER stress and A53T α-synuclein-mediated
aggregation [114]. In contrast, those that have lost their pdr-1
expression altogether are viable and do not display obvious defects
in their DA neurons [114]. These studies suggest that misfolded
parkin may be a relevant pathogenic factor in at least some of the
parkin-related PD cases.
2.3. PINK1
Like parkin, mutations in PINK1 are associated with recessive
parkinsonism [15,16]. However, very little is known to date about the
pathology of PINK1-related cases, although the loss or defective
function of DA neurons is likely to be the underlying pathology as
PINK1-related patients generally respond well to L-DOPA treatment.
Several recent studies involving pink1-deﬁcient ﬂies have provided
unequivocal evidence supporting a link between PINK1mutations and
mitochondrial dysfunction [115–117]. Two concurrent papers in 2006
by Clark et al. and Park et al. reported that pink1-deleted mutant
Drosophila are characterized by dramatic mitochondrial defects in
muscles and testes that include swelling and fragmentation of the
organelle, as well as reduction in ATP levels and mitochondrial DNA
content [115,116]. Otherwise, these pink1-deﬁcient ﬂies are viable,
although the males are sterile, and exhibit either no or mild loss of DA
neurons. Importantly, because the various phenotypes of pink1-
deﬁcient ﬂies bear striking resemblance to the observed character-
istics of parkin mutant ﬂies, the investigators examined whether the
two PD-related genes interact with each other functionally and found
that parkin over expression in pink1−/− ﬂies signiﬁcant ameliorated
all themutant phenotypes tested [115,116]. The reverse, however, does
not happen, i.e. PINK1 over expression in parkin null ﬂies does not
compensate for the loss of parkin function [115,116]. These observa-
tions were essentially corroborated by a separate but related study
conducted by Yang et al. that involved RNAi knockdown of pink in
Drosophila [118]. Yang et al. also extended the parkin rescue
experiment by demonstrating that DJ-1 over expression has no
mitigating effects on pink1 mutant phenotypes. Further, the investi-
gators showed that parkin protein level is reduced in pink1−/− ﬂies.
More recently, the same group also demonstrated a role for PINK1 as a
regulator of mitochondrial dynamics via the protein interaction with
the mitochondrial ﬁssion/fusion machinery [119]. The investigators
found that whereas PINK1 over expression promotes mitochondrial
ﬁssion, its inhibition results in excessive fusion of mitochondria [119].
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[120]. Together, these studies provide compelling evidence supporting
a role of PINK1 in maintaining mitochondrial homeostasis and
function, as well as a role for parkin as an important downstream
regulator of PINK1. It tempting to suggest that the interaction between
parkin and PINK1 occurs not only functionally, but also physically, and
in a linear pathway. Although the parkin protein resides primarily
outside the mitochondrion - a purported residence of PINK1, some
reports have suggested that a small amount of parkin associates with
this organelle [86,88]. Further, a recent study suggests that whilst the
PINK1 protein spans the outer mitochondrial membrane, its kinase
domain faces the cytoplasm [121]. Thus, a direct interaction between
parkin and PINK1 (at least at the cytosolic face of the mitochondria) is
not entirely inconceivable. Notably, an interaction between parkin and
PINK1 has been demonstrated in a co-transfection system [122].
However, whether this interaction takes place endogenously and at
the mitochondrial surface remains to be established.
Subsequent to the characterization of Drosophila pink1 mutants,
Kitada et al. reported the ﬁrst analysis of PINK1 deﬁciency in mice
[123] (Table 2). Similar to parkin null mice, PINK1 knockout mice do
not show any gross abnormality in the morphology and density of DA
cell bodies. There is also no reported presence of inclusion pathology
or locomotion defects. However, subtle nigrostrial deﬁcits are
detectable in these mice. PINK1-deﬁcient mice show a reduction in
evoked DA release (as recorded using striatal slices) that does not
appear to be associated with an increased reuptake of DA by DAT, but
rather reﬂects an impaired release mechanism. Further, intracellular
measurements of striatal medium spiny neurons revealed impair-
ments of corticostriatal long term potentiation and long term
depression that could be restored with DA receptor agonists, L-DOPA
or amphetamine, all of which promote DA neurotransmission. Since
mitochondrial abnormality is the central characteristic of pink1 null
ﬂies, Kitada et al. also examined whether this feature is present in
PINK1-deﬁcient mice but had mentioned in their report the lack of
overt mitochondrial morphological defects in these mice [123].
However, a follow-up study by the same group of investigators
revealed an increase in the number of larger mitochondria in the
striatum of PINK1 null mice [124], which supports the suggested role
of PINK1 in promoting mitochondrial ﬁssion [119,120]. Further,
impaired mitochondrial respiration attributable to defects in complex
I and also II-IV was also observed in the striatum of these mice. In
contrast, mitochondrial respiration is not altered in the cerebral cortex
of young (3–4 months) PINK1-deﬁcient mice but is signiﬁcantly
decreased in older (22–24months) knockout mice or when the young
mice are treated with exogenous stressors, suggesting that aging or
stress promotes mitochondrial dysfunction in these mice. Supporting
this, intra-nigral virus-mediated delivery of wild type PINK1, but not
its mutants, affords considerable protection against SN degeneration
in mice treated with MPTP [125]. In a related development,
J. Downward's group recently demonstrated that the mitochondrial
serine protease, Omi/HtrA2, is phosphorylated in a PINK1-dependent
manner upon activation of the p38 stress pathway [126]. Asmentioned
earlier, Omi/HtrA2 sequence variations have been associated with an
increased risk for PD [20,127], although a separate study revealed that
the Omi G399S disease variant is also found in neurologically normal
controls [21]. Interestingly, PINK1 also appears to phosphorylate the
mitochondrial chaperone TRAP1 [128] as well as interacts with Hsp90
[129]. Since Omi/HtrA2, TRAP andHsp90 all have chaperone functions,
it is conceivable that the susceptibility of PINK1-deﬁcient mitochon-
dria towards stress-induced impairment may be contributed by the
loss of PINK1 interaction with these effectors.
2.4. DJ-1
Mutations of DJ-1 associated with familial parkinsonism generally
occur in a recessive fashion [15].Whereas PINK1 has been identiﬁed tobe a mitochondrial-related protein kinase [16], the exact function of
DJ-1 is less clear. Several studies have suggested that DJ-1 operates as
an anti-oxidant protein [130,131]. Such a role of DJ-1 would be useful
in counteracting the well-recognized oxidative environment of DA
neurons. However, ablation of DJ-1 in mice did not accelerate DA
degeneration in the SN, even when the animals were aged up to
28 months [132–136] (Table 2). Further, there is neither accumulation
of inclusion bodies nor loss of LC neurons in the brains of these mice
[133,134]. Instead, DJ-1 null mice exhibit signiﬁcantly reduced DA
release in the striatum which occurs as a result of increased reuptake
of DA by the DA transporter (DAT) [132,134,136], although this
phenomenon is not observed in all the reported DJ-1 knockout lines
[135]. Consistent with this, DJ-1 null mice display generalized
hypokinesia in open ﬁeld tests [132,134,135]. Together, these observa-
tions suggest that DJ-1 deﬁciency could trigger motoric deﬁcits in the
absence of frank nigral neurodegeneration. However, in the absence of
robust pathology data from DJ-1 patients, it is difﬁcult to evaluate at
this moment whether the phenotype of DJ-1 null mice mirrors the
human condition. More recently, a related study revealed no
behavioural, neurochemical or anatomical deﬁcits in the DA system
of DJ-1 null mice [137]. The same study identiﬁed DJ-1 as an atypical
peroiredoxin-like peroxidase that functions to scavenge mitochon-
drial H2O2 through oxidation of its cysteine at position 106, a residue
on DJ-1 that was previously demonstrated by others via mutagenesis
and structural analyses to be modiﬁed by oxidative stress [131].
Notably, a pool of DJ-1 is known to be localized to the mitochondria
[131,138]. Supporting a role for DJ-1 in the mitochondria, the
investigators found increased levels of H2O2 in mitochondria isolated
from their DJ-1 knockout model [137]. Thus, the absence of DJ-1 may
predispose DA neurons to stress-induced degeneration. Indeed, DJ-1-
deﬁcient mice and ﬂies alike are hypersensitive to pharmacological
inducers of oxidative stress [118,136,139–142].
Unlike the mouse, the Drosophila contains two orthologs of the
human DJ-1, termed DJ-1α and DJ-1β that are expressed differentially,
i.e. whereas DJ-1β is ubiquitously expressed, the expression of DJ-1α
is restricted to themale germline [139,140]. Flies genetically ablated of
DJ-1β or both DJ-1α and DJ-1β show a full complement of DA neurons
[139,140,142], but the inactivation of DJ-1α expression via RNAi
resulted in an age-dependent reduction of TH-positive neurons in the
DMC, as revealed by immunostaining of parafﬁn brain sections [118].
Although some groups have also reported locomotion deﬁcits in DJ-1
mutant ﬂies [142,143], none of these studies have examined the
mutant ﬂies for mitochondrial pathology. Notwithstanding this, a
consistent observation amongst the different groups is that DJ-1
mutant ﬂies display a dramatically enhanced sensitivity to toxins that
induce oxidative stress [118,139,140,142], with aged ﬂies showing
further vulnerability to these agents [144]. Apparently, both the aging
process and oxidation challenge promote over-oxidation of DJ-1 at
Cys104 (analogous to Cys106 in human DJ-1) [144], a modiﬁcation
that could irreversibly inactivate the protein [137]. Collectively, these
studies support a role for DJ-1 in protecting neurons against oxidative
insults, and at the same time, suggest a mechanism by which DJ-1
function could be progressively lost through aging, and thereby an
increased risk for the demise of oxidation-prone DA neurons.
2.5. LRRK2
LRRK2 is a large protein (2527 amino acids) comprised of several
independent domains, one of which is a kinase domain capable of
exhibiting a GTP-dependent phosphorylation activity [145–147].
Mutations in LRRK2 are currently recognized to be the most common
genetic cause of parkinsonism, accounting for about 5–6% of patients
with familial PD and an unprecedented 1–3% prevalence in sporadic
PD [17,18]. The predominantly late-onset phenotype of LRRK2
mutation-related PD is clinically largely indistinguishable from
idiopathic PD, although the inclusions pathology that accompanies
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least 20 LRRK2 mutations have been identiﬁed to be causative of
autosomal dominant parkinsonism, with the G2019S missense
mutation being the most prevalent [148,149]. Several groups have
demonstrated an increase kinase activity for the LRRK2 G2019S
substitution, which concomitantly increases its toxicity [145–147,150–
152]. However, the phenomenon is not consistently observed for other
LRRK2 mutations. Notably, some LRRK2 mutations (e.g. I2012T)
appear to have reduced kinase activity instead [151], and several
LRRK2mutants also exhibit a propensity to aggregatewhen expressed
in cultured cells [147]. Thus, the exact mechanism by which LRRK2
mutations cause disease is not entirely clear at this moment.
Because of the prevalence of LRRK2 mutations, and the similarities
between LRRK2-induced parkinsonism and sporadic PD, there is much
enthusiasm in modelling LRRK2 dysfunction in animals. Although a
mouse model of LRRK2 has yet to be formally reported at the time of
this review preparation, a number of groups have recently reported
the analysis of LRRK2 mutant ﬂies. Consistent with its demonstrated
toxicity in cultured cells, Liu et al. found that the expression of human
LRRK2 G2019S mutant in the ﬂy's photoreceptor cells triggers marked
retinal degeneration. [153]. Interestingly, the same phenotype is
observed with eye-speciﬁc expression of wild type human LRRK2,
suggesting that de-regulated LRRK2 levels could also mediate
pathogenic outcomes. Importantly, pan-neuronal or DA neuron-
speciﬁc expression of both wild type and mutant human LRRK2 in
ﬂies results in adult-onset selective degeneration of TH-positive
neurons, as measured by confocal microscopy-based analysis of whole
mount ﬂy brains. Further, these ﬂies exhibit locomotor deﬁcits that
could be ameliorated by L-DOPA treatment. However, unlike parkin
mutant ﬂies, the observed loss of TH-positive neurons triggered by
LRRK2 over expression is not restricted to select DA clusters. Instead,
all the DA clusters in the ﬂy brain are similarly affected by LRRK2 over
expression. This is rather intriguing, considering that speciﬁc groups
of DA neurons are affected in LRRK2-related human PD cases. In
contrast, Lee et al. reported that transgenic ﬂies over expressing the ﬂy
orthologs of human wild type or disease-associated R1441C mutant
LRRK2 do not exhibit any signiﬁcant defects in the tissues examined,
including DA neurons and muscles [154]. Instead, the ablation of
endogenous dLRRK2 expression in ﬂies result in a reduction in TH-
immunostaining, speciﬁcally in the dorsomedial and posteriomedial
clusters [154]. However, a related study by another group revealed a
dispensable role of Drosophila ortholog of LRRK2 in the survival of DA
neurons, although the investigators observed that dLRRK2−/− ﬂies
are selectively sensitive to H2O2-induced stress [155]. Similarly, a very
recent report by Imai et al. suggests that dLRRK2 is not essential for the
maintenance of DA neurons. The group also characterized transgenic
ﬂies expressing Drosophila orthologs of human LRRK2 Y1699C or
I2020T mutants, which is of particular interest here in view of the lack
of phenotype in LRRK2 mutant-expressing ﬂies observed by Lee et al.
Likewise, Imai et al. reported no difference in the number of DA
neurons in 10-day-old mutant ﬂies, but a signiﬁcant loss of DA
neurons in PPL1 and PPM1/2 (but not PPM3 clusters) was recorded
when these ﬂies are 60-day of age. This result suggests that a
signiﬁcant length of time is required for LRRK2 mutants to manifest
their neurotoxicity in the ﬂy, a phenomenon that is consistent with
the typically late-onset phenotype of LRRK2-linked disease. Con-
ceivably, this time-dependent degenerationmay explainwhy Lee et al.
did not observe any loss of DA neurons in 30-day-old ﬂies expressing
orthologous LRRK2 R1441C mutant [154], although the speculation
remains to be proven. Importantly, Imai et al. identiﬁed the eukaryotic
initiation factor 4E-binding protein (4E-BP) as a substrate for LRRK2.
Notably, phosphorylation of 4E-BP relieves its inhibition on protein
translation, an energy-demanding process that could be detrimental
when unregulated especially in times of stress. Consistent with this,
Drosophila expressing LRRK2 mutants exhibit enhanced sensitivities
towards oxidative stress agents whereas ﬂies that are deﬁcient inLRRK2 expression are resistant. These results offer a novel pathogenic
mechanism by which LRRK2 mutations could result in an age-
dependent loss of DA neurons.
Another possible mechanism of LRRK2-induced neurotoxicty
comes from an elegant study performed in C. elegans by Sakaguchi
et al. [156]. The investigators demonstrated that deletion of
orthologous LRRK2 gene in C. elegans signiﬁcantly affects the transport
or sorting of synaptic vesicles (SVs) in the worm's neurons. Normally,
SVs are localized to the axonal regions but not to dendritic processes.
In LRRK2-deﬁcient worms, this polarized localization of SV proteins is
lost and SV proteins are found in both presynaptic as well as dendritic
endings of neurons. The axonal-dendritic polarity is however
unaffected in transgenic worms expressing wild type LRRK2. Inter-
estingly, the aberrant SV localization in LRRK2-deﬁcient worms could
be rescued by the introduction of an orthologous disease-associated
LRRK2 mutant (that corresponds to the human LRRK2 I2020T
mutation) but not by a kinase-inactive form of LRRK2. Together,
these results demonstrate a non-dispensable role for LRRK2 in the
polarized sorting of SV proteins to the axons and at the same time,
suggest a mechanism by which loss of LRRK2 function could also
result in neuronal dysfunction.
3. Concluding remarks
Although the discovery of familial PD-linked genes have provided
the opportunity to develop genetic models that hold promise to
recapitulate the chronic nature of the disease, it is rather disappoint-
ing that virtually none of the genetic mouse models of PD generated
thus far has managed to replicate the disease pathology and
progression faithfully. Further, conﬂicting observations amongst
different groups regarding the phenotypes displayed by the various
models are not infrequent. However, in retrospect, it might be a tall
order for animals living in controlled environment to recapitulate the
various features of a complex disease that typically requires several
decades to surface in humans, even in individuals with overt PD-
linked gene mutations. Perhaps a second (or multiple) hit present in
the environment at large is needed to promote overt DA degeneration
in these genetically-manipulated animals, as suggested by the
accelerated degeneration of DA neurons in DJ1−/−mice in response
toMPTP intoxication [141]. Surprisingly, themost dramatic phenotype
is observed in Drosophila PD models. Indeed, it remain intriguing that
some ﬂy models of PD could reproduce the salient features of the
human disease, including progressive degeneration of select subsets
of DA neurons and associated locomotion deﬁcits. However, it is
important to note that several major abnormalities outside the ﬂy's
nervous system occur just as frequently, if not more. Thus, not a single
model to date represents a perfect replica of the disease. Whether
mousemodels of LRRK2-induced parkinsonismwould eventually turn
out to be an ideal genetic model of the disease remains to be seen.
However, as mentioned earlier, the disease mechanism of LRRK2
dysfunction is not entirely clear at this moment. Although a dominant
gain of function mechanism is suspected, a dominant-negative or
haploinsufﬁciency mechanism is also plausible, particularly in view of
the abnormal phenotype in LRRK2-deﬁcient worms. How LRRK2-
linked parkinsonism should be best modelled is therefore academic.
Nonetheless, it is important to recognize that existing models have
collectively provided several important insights into the pathogenesis
of PD.
At least with loss-of-function PD mouse models, abnormality in
nigrostriatal DA neurotransmission seems to be a frequent, albeit
subtle, phenotypic characteristic that accompanies gene dysfunction.
Both PINK1−/− and DJ-1−/− mice, together with some mutant
synuclein-expressingmice, have been described to exhibit reduced DA
release, while the reverse is true for parkin mutant mice (Table 2) as
well as mice ablated of α-synuclein [157]. Whether defects in DA
release or reuptake mechanism precede and/or contribute to DA
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certainly warrants attention, especially in view of the association of
the phenomenon with not one but four PD-linked genes. A caveat is
that the above phenomena are not consistently observed amongst
different groups (Table 2). On the other hand, Drosophila PD models
have provided signiﬁcant insights into the relationship between
recessive PD-linked genes and mitochondrial function. The fact that
mitochondrial pathology in the ﬂy's ﬂight muscle is a major feature of
parkin and pink1 mutant ﬂies would suggest a non-trivial role for
these two proteins in maintaining mitochondrial homeostasis.
Further, DJ-1 also appears to participate directly or indirectly in
ensuring proper mitochondrial function. Moreover, mitochondrial
dysfunction is widely thought to underlie sporadic PD pathogenesis.
The obvious challenge now is to translate the ﬁndings obtained in
ﬂight muscles of ﬂies into neuronal cells, and to address alongside
whether and how mitochondrial impairment affects nigrostriatal DA
neurotransmission. At the same time, it would be important to
elucidate the nature of interaction(s) amongst the different PD-linked
gene products associated with mitochondrial homeostasis. The
clariﬁcations of these issues could provide clues to facilitate the
generation of a more representative genetic model of PD, and thereby
the development and assessment of therapeutic strategies.
In conclusion, despite the current lack of a representative model of
PD that accurately recapitulates the progressive process as well as the
nature and distribution of the human pathology, what we already
have from existing genetic models of PD is a wealth of information
waiting to be exploited. Rather than over-emphasizing on the lack of
robust PD phenotype in these models, it would be worthwhile to
examine more closely the subtle, but nonetheless, recurring pheno-
types of the various models that may represent important pre-clinical
features of the disease.
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